The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cells (APC). Natural APC are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APC can be damaged, absent or inactive.
The AIM technology holds great potential for use in immuno-therapy because aAPC can be readily engineered in such a way that a highly specific immune attack can be directed toward any foreign substance or cell type in a patient’s body.
NexImmune executives will attend the JP Morgan Healthcare Conference on January 12-15, 2015 in San Francisco, California.
Funding will support the development of AIM 101, a novel immuno-therapeutic agent for cancer